While the choice of treatment for age-related macular degeneration (AMD) is largely based on the experience and preference of the treating retinal specialist and patient preferences, payers are key stakeholders in impacting treatment selection through formulary placement, step therapy, and site-of-care policies which can affect member access. Based on findings from the 2022-2023 ManagedCareEye.com initiatives, disease state baseline knowledge and awareness has improved, but payers continue to need additional education to apply health plan best practices to improve AMD management and outcomes.
- Provider:Medical Education Resources
- Activity Link: https://www.managedcareeye.com/
- Start Date: 2024-06-30 05:00:00
- End Date: 2024-06-30 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 0.5 hours
Nursing: 0.5 hours
Pharmacy: 0.5 hours - Commercial Support: Source: Regeneron Pharmaceuticals, Inc. - Amount: 10000.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence
- Provider Ship: Jointly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest